MIST vs. RZLT, ERAS, TECX, SLDB, ITOS, ETON, ALT, CMPX, CYRX, and RVNC
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Rezolute (RZLT), Erasca (ERAS), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Altimmune (ALT), Compass Therapeutics (CMPX), CryoPort (CYRX), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry.
Milestone Pharmaceuticals vs. Its Competitors
Milestone Pharmaceuticals (NASDAQ:MIST) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.
Milestone Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Milestone Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 350.16%. Rezolute has a consensus target price of $11.83, suggesting a potential upside of 125.35%. Given Milestone Pharmaceuticals' higher probable upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Rezolute.
Milestone Pharmaceuticals has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Milestone Pharmaceuticals had 14 more articles in the media than Rezolute. MarketBeat recorded 17 mentions for Milestone Pharmaceuticals and 3 mentions for Rezolute. Rezolute's average media sentiment score of 0.58 beat Milestone Pharmaceuticals' score of 0.28 indicating that Rezolute is being referred to more favorably in the news media.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 18.4% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Rezolute's return on equity of -70.09% beat Milestone Pharmaceuticals' return on equity.
Summary
Milestone Pharmaceuticals beats Rezolute on 8 of the 15 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIST) was last updated on 7/16/2025 by MarketBeat.com Staff
Free MIST Stock Alerts